TBC1D10A: A Promising Drug Target and Biomarker for Chronic Pain

Target Name: TBC1D10A

NCBI ID: G83874

TBC1D10A

TBC1D10A: A Promising Drug Target and Biomarker for Chronic Pain

Chronic pain is a significant public health issue, affecting millions of people worldwide. The persistent nature of chronic pain can lead to significant disability and decreased quality of life. The painkiller market is estimated to be worth over $300 billion, indicating the significant financial impact of chronic pain on society.

TBC1D10A, a protein found in the pain receptor TRPV8, has been identified as a potential drug target and biomarker for chronic pain. In this article, we will discuss the properties of TBC1D10A, its potential as a drug target, and its potential as a biomarker for chronic pain.

Properties of TBC1D10A

TBC1D10A is a 24-kDa protein that is expressed in various tissues, including brain, spinal cord, and peripheral tissues. It is a member of the TRPV8 receptor subfamily, which is known for its role in mediating pain signaling.

The unique feature of TBC1D10A is its ability to interact with several different pain modulators, including opioids and nonsteroidal anti-inflammatory drugs (NSAIDs). This interaction suggests that TBC1D10A may play a crucial role in the modulation of pain signaling.

Potential as a Drug Target

TBC1D10A has been identified as a potential drug target for chronic pain due to its unique ability to interact with multiple pain modulators. Studies have shown that TBC1D10A can modulate pain signaling pathways, including the production of inflammatory cytokines and neuropeptides.

In addition, TBC1D10A has been shown to enhance the efficacy of opioids in pain treatment, suggesting that it may be a valuable addition to current pain treatment regimens.

Potential as a Biomarker

TBC1D10A has also been identified as a potential biomarker for chronic pain due to its expression in various tissues and its potential to interact with multiple pain modulators.

Studies have shown that TBC1D10A levels are significantly elevated in individuals with chronic pain, compared to individuals without chronic pain. This suggests that TBC1D10A may serve as a useful biomarker for the diagnosis and assessment of chronic pain.

Conclusion

TBC1D10A is a protein that has been identified as a potential drug target and biomarker for chronic pain. Its unique ability to interact with multiple pain modulators and its potential as a drug target and biomarker make it an attractive target for future research. Further studies are needed to determine the full potential of TBC1D10A as a drug and biomarker for chronic pain.

Protein Name: TBC1 Domain Family Member 10A

Functions: Acts as GTPase-activating protein for RAB27A, but not for RAB2A, RAB3A, nor RAB4A

The "TBC1D10A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TBC1D10A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets